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For at least 60 years, surgical resection has been a widelyused approach to the management of patients with lung
metastases from a variety of solid tumors. For many of these
patients, surgical resection has provided the only potentially
curative treatment. Analyses of numerous retrospective series
have led to well-accepted surgical selection criteria: a pri-
mary tumor that has been definitively controlled, metastases
limited to the lung that can be completely resected, ability of
the patient to tolerate the planned operation, and lack of a
better alternative treatment. The number of lung metastases,
the disease-free interval since treatment of the primary tumor,
the tumor doubling time, the presence of lymph node metas-
tases, the histology of the primary tumor, and in some
instances, elevated serum markers such as carcinoembryonic
antigen are known to influence outcome and may be incor-
porated into the decision of whether to offer surgery to the
patient. However, there remain many controversial aspects to
pulmonary metastasectomy, which are the subject of a
thoughtful review by members of the European Society of
Thoracic Surgeons in this issue of the Journal of Thoracic
Oncology. We lack definitive data on issues such as the
optimal preoperative imaging studies, when mediastinal
nodal staging should be performed before or during resection,
whether a minimally surgical approach (video-assisted tho-
racic surgery) allows adequate resection, under what circum-
stances reoperative pulmonary metastasectomy is appropri-
ate, how pulmonary metastasectomy should be integrated
with other treatments, and whether other local therapies such
as radiofrequency ablation or stereotactic radiotherapy offer
equivalent results.1–11
The management of patients with a previously treated
malignancy is further confounded by the fact that the devel-
opment of one or more new pulmonary nodules does not
always represent metastatic disease. Early surgical series
reported that approximately 5% of new lung nodules in
patients previously treated for breast and colon cancer proved
to be benign and up to half were found to be primary lung
carcinomas.12–14 The likelihood that a new lung nodule is a
metastasis as opposed to a second primary cancer is influ-
enced by the type of original malignancy. In patients whose
initial cancer was a sarcoma or melanoma, a new pulmonary
nodule is approximately 10 times more likely to be a metas-
tasis than a second primary cancer. If the original primary
tumor was a genitourinary or colorectal cancer, there is
approximately 50% chance that the new nodule is a metas-
tasis. If the original tumor was a head and neck cancer, the
new nodule is twice as likely to be a new primary lung cancer
than a metastasis. These findings are likely related to tobacco
exposure being the common etiology for primary malignan-
cies in multiple sites.15 Before assuming that a patient has
metastatic and potentially incurable disease, it is important to
establish a tissue diagnosis, either intraoperatively or before
initiating nonsurgical treatment. Fine needle aspiration may
yield sufficient tissue to distinguish between some primary
tumors (e.g., colon metastasis versus new lung adenocarci-
noma), but the pathologic differential diagnosis can be prob-
lematic for other tumors (e.g., metastatic breast versus pri-
mary lung adenocarcinoma) and may require more tissue.
Distinguishing between metastatic head and neck cancer and
primary lung squamous cell carcinomas is particularly diffi-
cult because squamous cell carcinomas from multiple sites
can appear morphologically identical to one another. Molec-
ular analyses, when available, may assist in this regard16 as
can the clinical scenario (e.g., disease-free interval since
treatment of primary tumor). Establishing a definitive tissue
diagnosis is especially important when considering non-
surgical local treatment modalities such as radiofrequency
ablation, stereotactic radiotherapy, or systemic therapy. It
is also critical to the design of clinical trials in this patient
population.
The history of pulmonary metastasectomy indicates
that it is a moving target—a procedure for which the indica-
tions are constantly evolving. In the era before effective
chemotherapy, pulmonary metastasectomy series included
large numbers of patients with osteogenic sarcoma and breast
cancer.17,18 These patients are now treated predominantly
with systemic therapy with only highly selected patients
considered for surgical resection.19 The advent of effective
chemotherapy for germ cell tumors changed pulmonary me-
tastasectomy from being a primary intervention to an adju-
vant treatment directed at detection and resection of minimal
residual cancer and removal of benign teratoma.20 A similar
evolution is now occurring in the management of metastatic
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colorectal and renal cancers. For decades, when there was
little effective systemic therapy for colorectal cancer, sur-
geons carefully refined the indications for pulmonary metas-
tasectomy in these patients.21,22 However, during the past
decade, the development of new effective chemotherapy and
of targeted therapies has radically altered the management of
patients with metastatic colorectal cancer. Resection of a
solitary metastasis in a patient with indolent disease, a normal
carcinoembryonic antigen, and no lymph node metastases
may still be the best approach, but how to integrate surgery
into the treatment of the majority of patients with colorectal
cancer and lung metastases is now undefined. Should we treat
them with systemic therapy only, administer chemotherapy as
induction or adjuvant treatment after pulmonary metastasec-
tomy, or “sandwich” surgery within a chemotherapy pro-
gram? The development of antiangiogenesis agents is rapidly
altering the management of patient with renal cell cancer.
Although pulmonary metastasectomy used to be the most
effective treatment for many of these patients, this is no
longer the case. When to perform pulmonary metastasectomy
in such cases is an open question.
Clearly, there is a need for prospective clinical trials in
patients being considered for pulmonary metastasectomy.
Some questions, such as the optimal approach to preoperative
imaging or the validity of minimally invasive surgery, would
be fairly straightforward to ask and answer. Because the
number of patients who are candidates for pulmonary metas-
tasectomy in any single institution is relatively small, such
trials would be best performed in a multicenter setting. The
question of therapeutic benefit, especially in patients for
whom effective chemotherapy now exists, is much harder to
answer. The planned randomized trial described by Tom
Treasure in this issue of the Journal of Thoracic Oncology is
an ambitious effort to define optimal treatment for patients
with metastatic colorectal cancer. In the era of both rapidly
evolving molecular medicine and technology, it can be in-
creasingly difficult to perform randomized controlled trials
that attempt to determine the benefit of surgical resection.
Such trials require many years to develop and perform.
During the past decade, we have repeatedly seen that the
discovery of a single critical molecular abnormality and the
development of therapies directed to that abnormality can
revolutionize, almost overnight, the treatment of a malig-
nancy. Witness, for example, the recent changes in treatment
that have occurred in the treatment of chronic myelogenous
leukemia, gastrointestinal stromal tumors, epidermal growth
factor receptor-mutant lung adenocarcinomas, breast cancer,
colon cancer, and renal cell cancer. Major technological
improvements in radiotherapy and ablative therapies also
have the potential to alter the indications for surgery or
render surgical intervention obsolete. There are many
important questions that need to be answered in patients
thought to be candidates for pulmonary metastasectomy.
Selecting the best questions and designing the clinical
trials that could lead to durable results is the big challenge.
The members of the European Society of Thoracic Sur-
geons deserve credit for assessing our current state of
knowledge about pulmonary metastasectomy in a way that
could frame future clinical trials.
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